Aeluma, Inc. filings document the reporting record of a Nasdaq-listed emerging growth semiconductor company developing scalable photonic and electronic technologies. Its periodic and current reports cover financial results, quarterly reporting, Regulation FD materials, investor presentations and public-company disclosure controls.
The company’s SEC filings also describe capital-structure activity involving common stock, shelf registration, underwriting agreements and sales-agreement arrangements for registered equity issuance. Governance disclosures include annual meeting voting results, director elections and shareholder approvals, while other current reports address material definitive agreements and Rule 10b5-1 trading-plan disclosures.
Aeluma, Inc. reports an amended Schedule 13G/A showing reduced ownership. Mark N. Tompkins now reports 885,000 shares of Common Stock, representing 4.83% of the class based on May 8, 2026 outstanding shares. The amendment states this is an exit filing because the reporting person ceased to be a beneficial owner of more than 5%. The filing notes the reported percentage is calculated from 18,305,335 shares outstanding as of May 8, 2026 and that the reported amount includes the reporting person’s beneficial ownership as of March 31, 2026.
Aeluma, Inc. reported higher revenue but a larger loss for the nine months ended March 31, 2026. Revenue rose to $3.9 million from $3.3 million, driven mainly by government contracts, while operating expenses more than doubled to $9.7 million as the company expanded headcount, materials purchases, and stock-based compensation.
Net loss widened to $5.1 million from $2.2 million, partly offset by other income of $668 thousand from interest on cash and investments. Cash, cash equivalents, and a certificate of deposit totaled $37.8 million as of March 31, 2026, up from $15.7 million, largely due to two underwritten equity offerings that raised net proceeds of $12.6 million and $23.4 million.
The company entered several new government contracts and had remaining performance obligations of $8.9 million, with revenue highly concentrated in U.S. government customers. Aeluma also put in place a $50 million at-the-market equity program that had not been utilized by quarter end. Management disclosed that disclosure controls and procedures remained ineffective due to limited finance staffing, although remediation efforts are underway.
Aeluma, Inc. reported third quarter fiscal 2026 results showing modest revenue and ongoing investment-driven losses. Revenue for the three months ended March 31, 2026 was $1,222 thousand, while the company recorded a GAAP net loss of $1,800 thousand, or $(0.10) per basic and diluted share. For the nine-month period, revenue reached $3,879 thousand with a net loss of $5,146 thousand.
On a non-GAAP basis, which excludes items such as stock-based compensation and certain non-cash charges, Aeluma reported a third quarter net loss of $701 thousand and adjusted EBITDA of $(911) thousand. The company ended March 31, 2026 with $37,780 thousand in cash and cash equivalents, supporting its manufacturing and commercialization priorities.
Aeluma narrowed full fiscal 2026 revenue guidance to $4.2 million to $4.6 million, from a prior range of $4.0 million to $6.0 million, citing delays in contract execution related to government shutdowns and other factors. Management highlighted six new development engagements totaling $5 million and emphasized growing interest tied to AI data center and photonics demand.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported multiple insider transactions in the company’s common stock. On May 1, 2026, he completed open-market sales totaling 20,000 shares at prices ranging from $23.62 to $26.02 per share, executed under a Rule 10b5-1 trading plan adopted on December 3, 2025.
The filing also shows ten bona fide gifts of common stock totaling 3,133,990 shares between December 19, 2025 and May 1, 2026, including a December 2025 transfer of 1,476,995 shares to a family trust for estate-planning purposes, where Klamkin and his spouse serve as sole trustees. Following these transactions, he continues to hold Aeluma shares directly and through the family trust as reported.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin sold 20,000 shares of common stock in an open-market transaction on April 1, 2026. The shares were sold at a weighted average price of $13.0975 per share, with individual sale prices ranging from $12.82 to $13.325 per share.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2025. Following these transactions, Klamkin directly holds 1,409,398 shares of Aeluma common stock.
Aeluma, Inc. reports a 5.6% stake held by boisei investments llc (via George Perry) totaling 1,000,000 shares of Common Stock. The filing states 1,000,000 shares are beneficially owned with sole voting and dispositive power. The issuer reported 18,002,949 shares outstanding as of March 17, 2026.
The obligation to file was triggered on March 30, 2026 when beneficial ownership was 994,466 shares; the reported amount reflects ownership as of March 31, 2026. George Perry signs as President of boisei investments llc, which is owned through boisei labs llc.
Aeluma, Inc. entered into a Sales Agreement that allows it to issue and sell up to $50.0 million of its common stock from time to time through a group of sales agents. Any shares will be offered under an effective Form S-3 shelf registration statement.
Sales, if made, will occur as ordinary brokers’ transactions on the Nasdaq Capital Market at market prices or as otherwise agreed with the agents. Neither Aeluma nor the agents are obligated to sell or purchase shares, and either party can terminate the agreement with five business days’ written notice.
Aeluma, Inc. has launched an at-the-market offering under a Sales Agreement dated March 20, 2026, authorizing up to $50,000,000 aggregate offering price of common stock. Sales may occur from time to time through Roth Capital Partners as representative and three agent firms, with commissions up to 3%.
The prospectus supplement bases the illustrative share count on 18,002,949 shares outstanding as of March 17, 2026 and shows up to 3,556,187 shares would be issued if $50,000,000 were sold at the March 19, 2026 closing price of $14.06. Proceeds are intended for working capital and general corporate purposes; timing and amounts will vary with market sales.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported open-market sales of a total of 50,000 shares of Aeluma common stock on March 4, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The transactions consisted of 28,206 shares sold at a weighted average price of $17.7746 per share, with individual sale prices ranging from $17.11 to $18.10, and 21,794 shares sold at a weighted average price of $18.4110 per share, with prices ranging from $18.11 to $19.03.
Following these sales, Klamkin directly owned 1,429,398 shares of Aeluma common stock.